Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection

Michele Spina, Jean Gabarre, Giuseppe Rossi, Marco Fasan, Clara Schiantarelli, Ezio Nigra, Maurizio Mena, Andrea Antinori, Adriana Ammassari, Renato Talamini, Emanuela Vaccher, Giampiero Di Gennaro, Umberto Tirelli

Research output: Contribution to journalArticlepeer-review


A phase 2 prospective study was performed to evaluate the feasibility and activity of a short, dose-intensive chemotherapy regimen and radiotherapy (the Stanford V regimen) plus highly active antiretroviral therapy (HAART) and granulocyte colony-stimulating factor (G-CSF) support in patients with Hodgkin disease and HIV infection. Fifty-nine patients were enrolled. Stanford V was well tolerated and 69% of the patients completed treatment with no dose reduction or delayed chemotherapy administration. The most important dose-limiting side effects were bone marrow toxicity and neurotoxicity. Complete remission was achieved by 81% of the patients, and after a median follow-up of 17 months 33 patients (56%) were alive and disease-free. The estimated 3-year overall survival (OS), disease-free survival (DFS), and freedom from progression (FFP) were 51%, 68%, and 60%, respectively. Probability of FFP was significantly (P = .02) higher among patients with an International Prognostic Score (IPS) of 2 or lower than in those with an IPS higher than 2, and the percentages of FFP at 2 years in these groups were 83% and 41%, respectively. Similarly, the probability of OS was significantly (P =.0004) different in the 2 groups, and the percentages of OS at 3 years were 76% and 33%, respectively. Our data confirm that the Stanford V regimen with concomitant HAART is feasible and active in an HIV setting. However, a more intensive approach should be considered in patients with high IPSs.

Original languageEnglish
Pages (from-to)1984-1988
Number of pages5
Issue number6
Publication statusPublished - Sept 15 2002

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection'. Together they form a unique fingerprint.

Cite this